Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase

被引:39
作者
Cui, JingXia [2 ]
Li, ChunLei [1 ]
Wang, CaiXia [1 ]
Li, YanHui [1 ]
Zhang, Lan [1 ]
Zhang, Li [1 ]
Yang, HaiYan [2 ]
机构
[1] ZhongQi Pharmaceut Technol Shijiazhuang Co Ltd, Shijiazhuang 050051, Hebei Province, Peoples R China
[2] Hebei Med Univ, Sch Pharm, Shijiazhuang 050017, Hebei Province, Peoples R China
关键词
D O I
10.1211/jpp/60.12.0011
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Upon repeated administration, empty pegylated liposomes lose their long-circulating characteristics, referred to as the accelerated blood clearance (ABC) phenomenon. To investigate whether cytotoxic drug-containing pegylated liposomes could also elicit a similar phenomenon, two pegylated liposomal antitumour drugs (doxorubicin and mitoxantrone) were prepared, and they were administrated twice in the same animals with a 10-day interval at a dose level of 8 mg kg(-1) (pegylated liposomal doxorubicin) and 4 mg kg (1) (pegylated liposomal mitoxantrone). By comparing the overall pharmacokinetics after a single-dose injection with that in animals treated with two doses, it was surprising to find that repeated administration of pegylated liposomal antitumour drugs caused the disappearance of rapid distribution phase instead of the ABC phenomenon, resulting in the conversion of a two-compartment model to a one-compartment model. Further investigation revealed that repeated injection induced the decreased uptake of liposomal antitumour drugs by the spleen at the early time point of 0.5-8 h after injection. In contrast, the deposition of liposomal antitumour drugs into liver was not affected. Therefore, the disappearance of the rapid distribution phase might be related to the reduced spleen uptake at the early time point.
引用
收藏
页码:1651 / 1657
页数:7
相关论文
共 34 条
[1]
Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: Pharmacokinetics in mice [J].
Ahmad, A ;
Wang, YF ;
Ahmad, I .
LIPOSOMES, PT E, 2005, 391 :176-185
[2]
Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[3]
LONG-CIRCULATING (STERICALLY STABILIZED) LIPOSOMES FOR TARGETED DRUG-DELIVERY [J].
ALLEN, TM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :215-220
[4]
From conventional to stealth liposomes a new frontier in cancer chemotherapy [J].
Cattel, L ;
Ceruti, M ;
Dosio, F .
TUMORI, 2003, 89 (03) :237-249
[5]
Polyethylene glycol-liposomal doxorubicin - A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma [J].
Coukell, AJ ;
Spencer, CM .
DRUGS, 1997, 53 (03) :520-538
[6]
Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? [J].
Cui, JingXia ;
Li, ChunLei ;
Guo, WenMin ;
Li, YanHui ;
Wang, CaiXia ;
Zhang, Li ;
Zhang, Lan ;
Hao, Yanli ;
Wang, YongLi .
JOURNAL OF CONTROLLED RELEASE, 2007, 118 (02) :204-215
[7]
Drummond DC, 1999, PHARMACOL REV, V51, P691
[8]
Mechanism of action of mitoxantrone [J].
Fox, EJ .
NEUROLOGY, 2004, 63 (12) :S15-S18
[9]
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies [J].
Gabizon, A ;
Shmeeda, H ;
Barenholz, Y .
CLINICAL PHARMACOKINETICS, 2003, 42 (05) :419-436
[10]
Polyethylene glycol coated (pegylated) liposomal doxorubicin - Rationale for use in solid tumours [J].
Gabizon, A ;
Martin, F .
DRUGS, 1997, 54 (Suppl 4) :15-21